These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8156964)

  • 41. Fluctuations in salivary carbamazepine and carbamazepine-10,11-epoxide concentrations during the day in epileptic children.
    Paxton JW; Aman MG; Werry JS
    Epilepsia; 1983 Dec; 24(6):716-24. PubMed ID: 6641647
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bioavailability study of two carbamazepine containing sustained release formulations after multiple oral dose administration.
    Wangemann M; Retzow A; Evers G; Mazur D; Schug B; Blume H
    Arzneimittelforschung; 1998 Dec; 48(12):1131-7. PubMed ID: 9893926
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Response to carbamazepine in children with newly diagnosed partial onset epilepsy.
    Holland KD; Glauser TA
    Neurology; 2007 Aug; 69(6):596-9. PubMed ID: 17679679
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Patterns of care, outcomes, and direct health plan costs of antiepileptic therapy: a pharmacoeconomic analysis of the available carbamazepine formulations.
    Garnett WR; Gilbert TD; O'Connor P
    Clin Ther; 2005 Jul; 27(7):1092-103. PubMed ID: 16154489
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Carbamazepine neurotoxic reaction after administration of diltiazem.
    Maoz E; Grossman E; Thaler M; Rosenthal T
    Arch Intern Med; 1992 Dec; 152(12):2503-4. PubMed ID: 1456863
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical monitoring during carbamazepine slow-release, once-daily monotherapy.
    Stefan H; Schäfer H; Kuhnen C; Schneider S
    Epilepsia; 1988; 29(5):571-7. PubMed ID: 3137020
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy.
    Sachdeo RC; Sachdeo SK; Walker SA; Kramer LD; Nayak RK; Doose DR
    Epilepsia; 1996 Aug; 37(8):774-80. PubMed ID: 8764818
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Carbamazepine-induced skin rash in children with epilepsy.
    Konishi T; Naganuma Y; Hongo K; Murakami M; Yamatani M; Okada T
    Eur J Pediatr; 1993 Jul; 152(7):605-8. PubMed ID: 8354323
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Criteria to assess in vivo performance and bioequivalence of generic controlled-release formulations of carbamazepine.
    Bialer M; Yacobi A; Moros D; Levitt B; Houle JM; Munsaka MS
    Epilepsia; 1998 May; 39(5):513-9. PubMed ID: 9596204
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical evidence of fluconazole-induced carbamazepine toxicity.
    Ulivelli M; Rubegni P; Nuti D; Bartalini S; Giannini F; Rossi S
    J Neurol; 2004 May; 251(5):622-3. PubMed ID: 15164201
    [No Abstract]   [Full Text] [Related]  

  • 51. Steady state pharmacokinetics of carbamazepine-phenobarbital interaction in patients with epilepsy.
    Sennoune S; Iliadis A; Bonneton J; Barra Y; Genton P; Mesdjian E
    Biopharm Drug Dispos; 1996 Mar; 17(2):155-64. PubMed ID: 8907722
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Double-blind withdrawal of phenytoin and carbamazepine in patients treated with progabide for partial seizures.
    Leppik IE; Brundage RC; Krall R; Cloyd JC; Bowman-Cloyd T; Jacobs MP
    Epilepsia; 1986; 27(5):563-8. PubMed ID: 3093214
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neuroocular side effects of carbamazepine and phenobarbital in epileptic patients as measured by saccadic eye movements analysis.
    Tedeschi G; Casucci G; Allocca S; Riva R; Di Costanzo A; Tata MR; Quattrone A; Baruzzi A; Bonavita V
    Epilepsia; 1989; 30(1):62-6. PubMed ID: 2912718
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Carbamazepine and its epoxide: relation of plasma levels to toxicity and seizure control.
    Theodore WH; Narang PK; Holmes MD; Reeves P; Nice FJ
    Ann Neurol; 1989 Feb; 25(2):194-6. PubMed ID: 2919868
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Auditory disturbance induced by carbamazepine administration in a patient with secondary generalized seizure].
    Mabuchi K; Hayashi S; Nitta E; Takamori M
    Rinsho Shinkeigaku; 1995 May; 35(5):553-5. PubMed ID: 7664529
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intradose and circadian variation in circulating carbamazepine and its epoxide in epileptic patients: a consequence of autoinduction of metabolism.
    Macphee GJ; Butler E; Brodie MJ
    Epilepsia; 1987; 28(3):286-94. PubMed ID: 3582293
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A comparative pharmacokinetic study of conventional and chewable carbamazepine in epileptic patients.
    Patsalos PN
    Br J Clin Pharmacol; 1990 May; 29(5):574-7. PubMed ID: 2350535
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Acute cholangitis induced by carbamazepine.
    La Spina I; Secchi P; Grampa G; Uccellini D; Porazzi D
    Epilepsia; 1994; 35(5):1029-31. PubMed ID: 7925147
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Implications of metabolic parameters of carbamazepine in the therapeutic monitoring of Tunisian patients with epilepsy.
    Chbili C; Hassine A; Ben Amor S; Nouira M; Ben Ammou S; Saguem S
    Rev Neurol (Paris); 2016; 172(4-5):313-7. PubMed ID: 27062293
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulation.
    Konsil J; Dechasathian S; Mason DH; Stevens RE
    J Pharm Pharm Sci; 2002; 5(2):169-75. PubMed ID: 12207869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.